NDAORALTABLETPriority Review
Approved
Nov 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
9
Data completeness
3/8 — Basic
Priority Review
BLOCADREN (timolol maleate) by Merck & Co. is components: dorzolamide hydrochloride and timolol maleate. First approved in 1981.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BLOCADREN (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent approved in 1981 for oral use. It reduces elevated intraocular pressure by decreasing aqueous humor secretion and is indicated for glaucoma and ocular hypertension management. The drug works by blocking beta-1 and beta-2 adrenergic receptors without intrinsic sympathomimetic or membrane-stabilizing activity.
LOE Approaching
Product faces approaching loss of exclusivity with moderate competitive pressure (30% intensity), signaling transition toward generic defense and niche positioning strategies.
Mechanism of Action
components: Dorzolamide hydrochloride and timolol maleate. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma, by reducing aqueous humor secretion. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (9)
Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).
Started Mar 2021
84 enrolled
Primary Open Angle GlaucomaOcular Hypertension
Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Started Dec 2020
323 enrolled
Primary Open Angle GlaucomaOcular Hypertension
A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study
Started Sep 2018
417 enrolled
Glaucoma and Ocular Hypertension
A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study
Started Sep 2018
426 enrolled
Glaucoma and Ocular Hypertension
Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%
Started Jul 2018
590 enrolled
Glaucoma, Open-AngleOcular Hypertension
Worked on BLOCADREN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.